Top Tweets for #AVELUMAB
🎥 At #ESMO25, Enrique Grande (@drenriquegrande) discusses Phase II DISCUS trial in advanced #UrothelialCarcinoma.
3 vs 6 cycles of platinum chemo before maintenance #Avelumab showed similar efficacy but better QoL & fewer high-grade toxicities. 💊
Watch: https://t.co/PJQMG3iItM
#Oncology #bcsm #gism @myESMO
Os mostramos el estudio multicéntrico en @sefhcongreso sobre #avelumab en cáncer urotelial avanzado/metastásico.
📌En vida real, demuestra efectividad en SLP y SG1 con un perfil de toxicidad manejable
#posterFarmaCHUAC #sefh25 #posterea

According to results from the #Averectal study, the addition of #mFOLFOX6 and #avelumab to neoadjuvant short-course #radiotherapy, followed by total mesorectal excision, improved outcomes among patients with locally advanced MSS rectal cancer. Learn more: https://t.co/Fy35FfUflY

👉 #Avelumab switch maintenance therapy has been found to significantly improve OS and QoL in patients aged 65 years and older with advanced #urothelial carcinoma based on new outcomes from JAVELIN Bladder 100.
📺 Watch @PGrivasMDPhD discuss the latest data: https://t.co/XlBfpKkYyL
#Avelumab Combo Improves Long-Term Efficacy Vs #Sunitinib in Advanced RCC
👇
Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.
#renalcellcarcinoma #urooncology
https://t.co/d8v79kgFxM

We have several accruing #ClinicalTrials for patients with #SmallCell #BladderCancer
1. #Lurbi +/- #Avelumab LASER
https://t.co/pswVh8eMyT
2. #SG +/- #Atezo SMART
https://t.co/dOxmuq6E5i
3. #CaboNivoIpi ICONIC
https://t.co/3Aghb8BKZq [email protected] / ☎️240-760-6006

@tompowles1 delivers fascinating #GHFLecture for @QMBCI Awards
Some provocative statements:
"In 3yrs, 70% of #MIBC pts won't have #cystectomy but #avelumab instead"
"I think we'll stop using tissue banks very soon"
"If I started my career again I'd go to China more than Europe"!

Now great results of AXAGIST trial from @NIO_PIB presented in @RoswellPark by @rutkowskip1972 during 🇺🇸🇵🇱 meeting on #oncology #research #GIST #sarcoma #axitinib #avelumab #immunotherapy #TKI

Thank you France 2 about this great TV report of our Trophamet trial testing #avelumab in #gestational trophoblastic cancer with 96% disease cure presented @myESMO 2024. @afpfr @CHUdeLyon @ArcagyGineco
Cette petite s’appelle Joyce, hymne à la joie. Sa naissance est un miracle. Car sa maman a affronté avant elle un cancer de la grossesse. Des résultats spectaculaires sont annoncés : 96% de guérison pr ces patientes qui pensaient avoir un bébé et ont découvert une tumeur #ESMO24
Congrats @rutkowskip1972 and team for presenting their #investigatorinitiated AXAGIST #study on #axitinib and #avelumab in refractory #GISTs. Disease control rate of up to 70% in this hard to treat group! #sarcoma #ESMO24 #drugdevelopment #CTOSTweeTOS

@BonumCe @TiansterZhang @tompowles1 @MattMilowsky @ravikanesvaran @YujiMiura5 @koshkin85 @OncBrothers @MichvdHeijden @apolo_andrea @DrChoueiri @drenriquegrande @FabioSchutz78 @CaPsurvivorship @AmandaNizamMD @angiesmith_uro @FaltasLab @CharleneMantia @eugene_pietzak @HemOncFellows @JoshMeeks @Uromigos @DrKarineTawagi @LauraBukavinaMD @nataliagandur @MosheOrnsteinMD @neerajaiims @AlexHermen @A_Carrion_Puig @AlisonBirtle @ch_ohlmann @GGiannarini @amerseburger @AndreaNecchi @Ric_Campi @DrScottTagawa @pcvblack @spsutkaMD @PauloBergerot @SimaPorten @TDorffOnc @DrTFriedlander @sonpavde @shilpaonc @OncoBellmunt @ERPlimackMD @montypal @MattGalsky @DrRosenbergMSK 13/💡Pts should receive 1L avelumab maintenance if no progression w/ platinum chemoTx
✅Avelumab: an anti–PD-L1 w dual MoA
🎯PD-L1 blockade➡️antitumor immune response
🎯NK cell-mediated antibody-dependent cell-mediated cytotoxicity
@y_loriot #gucsm #JAVELINBladder100 #avelumab
This work is a result of our multi-institutional database which includes >1700 pts with #bladdercancer. We included adults with UC who received adjuvant ICI, 1L/upfront ICI, switch maintenance #avelumab (mAV), or ≥ 2L ICI with available tissue TMB or MSI data (2/7)

Podcast on mUC and how maintenance avelumab fits into the global 1L paradigm - @jgong15 (@CedarsSinai)
@MReimersMD (@WUSTL), @EMDSerono
https://t.co/mSf0Q01Kwi
#Podcasts #Oncology #mUC #Cancer #Research #Avelumab #OncoDaily
First oral abstract presentation at #ASCO24 by Prof Conte 🇮🇹 showing potential role of adjuvant #avelumab in patients with high-risk triple-negative early #BreastCancer (mostly no pCR after neoadjuvant chemotherapy)
@OncoAlert #bcsm

Dr. Blanc @UniBasel AURA rand PhII trial neoadj #avelumab + ddMVAC or cis-gem (CS) in #MIBC
Cis-eligible pCR 58-62% w/improved EFS & OS correlates w/pCR
Cis-ineligible pCR 32% w/avelumab alone w/lower EFS & OS
#ASCO24 @OncoAlert

Dr Kim from #DongA University in 🇰🇷 presented their #investigator-initiated study for anti-PDL1 #avelumab with #paclitaxel in #angiosarcomas. ORR 50%! Look at that waterfall plot! 😀 #sarcomas #ASCO24 @CTOsTweeTOS

@BonumCe 3/#MedTwitter #OncTwitter #gucsm #MetastaticUrothelialCarcinoma #BladderCancer #mUC
#CME🏅➡️https://t.co/N13zPdVJN2
🟢Pre-poll question 2️⃣
📊In #JAVELINBladder100 trial, what was the OS rate at 1 year for patients treated with #avelumab maintenance therapy?
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users

Elon Musk 
@elonmusk
241.5M followers

Barack Obama 
@barackobama
118.8M followers

Cristiano Ronaldo 
@cristiano
114.5M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
107.1M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.3M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.5M followers

Kim Kardashian 
@kimkardashian
70.9M followers

YouTube 
@youtube
68.8M followers

Neymar Jr 
@neymarjr
66.5M followers

Bill Gates 
@billgates
65.3M followers

Selena Gomez 
@selenagomez
63.1M followers

The Ellen Show
@theellenshow
62.2M followers

CNN 
@cnn
61.7M followers

X 
@x
60.7M followers










































